Accepted for Publication: April 12, 2022.
Published Online: July 11, 2022. doi:10.1001/jamaneurol.2022.1783
Corresponding Author: Nicoline Schiess, MD, MPH, Brain Health Unit, Department of Mental Health and Substance Use, World Health Organization, Avenue Appia 20, Geneva 1202, Switzerland (schiessn@who.int).
Conflict of Interest Disclosures: Dr Schiess has received grants from Edmond J. Safra Foundation paid to her institution during the conduct of the study. Dr Okun serves as a consultant for the Parkinson’s Foundation; has received research grants from the National Institutes of Health (NR014852, R01NS096008, U01NS119562, UH3 NS18-023, R21NS072897, R25NS108939), the Parkinson’s Foundation, the Michael J. Fox Foundation, the Smallwood Foundation, the Tourette Syndrome Association of America, and the UF Foundation; has received royalties for book publications with Demos, Manson, Amazon, Smashwords, Books4Patients, Perseus, Robert Rose, Oxford, and Cambridge; is an Associate Editor for New England Journal of Medicine Journal Watch Neurology; and has participated in CME and educational activities on movement disorders sponsored by the Academy for Healthcare Learning, PeerView, Prime, WebMD/Medscape, Medicus, MedNet, American Academy of Neurology, Movement Disorders Society, and Vanderbilt University. Dr Dorsey has received personal fees from the American Academy of Neurology, American Neurological Association, Excellus BlueCross BlueShield, International Parkinson’s and Movement Disorders Society, National Multiple Sclerosis Society, Northwestern University, Physicians Education Resource, PRIME Education, Stanford University, Texas Neurological Society, and Weill Cornell Honoraria; consulting fees from Abbott, AbbVie, Acadia, Acorda, Bial-Biotech Investments, Biogen, Boehringer Ingelheim, California Pacific Medical Center, Caraway Therapeutics, Curasen Therapeutics, Denali Therapeutics, Eli Lilly, Genentech/Roche, Grand Rounds, Huntington Study Group, Informa Pharma Consulting, Karger Publications, LifeSciences Consultants, MCM Education, Mediflix, Medopad, Medrhythms, Merck, Michael J. Fox Foundation, North American Center for Continuing Medical Education, Neurocrine, NeuroDerm, National Institutes of Health, Novartis, Origent Data Sciences, Otsuka, Physician’s Education Resource, Praxis, PRIME Education, Roche, Brown, McCarthy & Gruber, Sanofi, Seminal Healthcare, Spark, Springer Healthcare, Sunovion Pharma, Theravance, Voyager, and WebMD; grants from Biogen, Biosensics, Burroughs Wellcome Fund, CuraSen, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, Pfizer, PhotoPharmics, Safra Foundation, and Wave Life Sciences; has performed editorial services for Karger Publications; owns stock in Included Health and Mediflix; and has ownership interests in SemCap outside the submitted work. Dr Bloem has received grants and personal fees from UCB and Zambon paid to his institution; personal fees from Critical Path Institute, AbbVie, Biogen, Roche, GE Healthcare, Novartis, and Bial paid to his institution during the conduct of the study; grants from the Netherlands Organisation for Scientific Research, Michael J. Fox Foundation, Stichting Woelse Waard, Alkemade Keuls, Maag Lever Darm Stichting, ParkinsonNL, Davis Phinney Foundation, Parkinson’s Foundation, Verily, Horizon 2020, Nothing Impossible, and Parkinson Vereniging outside the submitted work. Dr Bhidayasiri has received grants from Thailand Science Research and Innovation, Thailand Research Fund, and Chulalongkorn University; personal fees from Royal Society of Thailand, Abbott Pharmaceuticals, Lundbeck Pharmaceuticals, Teva Pharmaceuticals, Eisai Pharmaceuticals, and Otsuka Pharmaceuticals outside the submitted work; and has patents for laser-guided walking stick issued to Chulalongkorn University, for laser-guided walking stick issued, for nocturnal monitoring device issued, for tremor analysis device issued, and for a Parkinson cup pending. Dr Chishimba has received personal fees from Northwestern Medicine outside the submitted work. Dr Chowdhary has received grants from Edmond J. Safra Foundation during the conduct of the study. Dr Fung has received grants from AbbVie and nonfinancial support from Merz outside the submitted work. Dr Gifford has received personal fees from Michael J. Fox Foundation, Parkinson Canada, and University of Rochester outside the submitted work; and is president and cofounder of PD Avengers. Dr Kühn has received personal fees from Medtronic, Boston Scientific, Teva, and Abbott outside the submitted work. Dr Lim has reeived personal fees from Medtronic outside the submitted work. Dr Okubadejo has received grants from Michael J. Fox Foundation outside the submitted work. Dr Dua has received grants from Edmond J. Safra Foundation during the conduct of the study. No other disclosures were reported.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the World Health Organization. Dr Okun is Associate Editor of JAMA Neurology, but he was not involved in any of the decisions regarding review of the manuscript or its acceptance.
Additional Contributions: We gratefully acknowledge the contributions of the Edmond J. Safra Foundation for their financial support of the WHO consultation workshop, “Addressing the Public Health Importance of Parkinson Disease.”
4.Dorsey
R , Sherer
T , Okun
MS , Bloem
B . Ending Parkinson’s Disease: A Prescription for Action. Hatchette Book Group, Inc; 2020.
6.Yang
W , Hamilton
JL , Kopil
C ,
et al. Current and projected future economic burden of Parkinson’s disease in the U.S.
NPJ Parkinsons Dis. 2020;6:15.
PubMedGoogle ScholarCrossref 7.Bovolenta
TM , de Azevedo Silva
SM , Arb Saba
R , Borges
V , Ferraz
HB , Felicio
AC . Systematic review and critical analysis of cost studies associated with Parkinson’s disease.
Parkinsons Dis. 2017;2017:3410946. doi:
10.1155/2017/3410946PubMedGoogle ScholarCrossref 16.Subramanian
I , Mathur
S , Oosterbaan
A , Flanagan
R , Keener
AM , Moro
E . Unmet needs of women living with Parkinson’s disease: gaps and controversies.
Mov Disord. 2022;37(3):444-455. doi:
10.1002/mds.28921PubMedGoogle ScholarCrossref 17.Shalash
A , Okubadejo
NU , Doumbe
J ,
et al. Translation, validation, diagnostic accuracy, and reliability of screening questionnaire for parkinsonism in three African countries.
J Parkinsons Dis. 2020;10(3):1113-1122. doi:
10.3233/JPD-202040PubMedGoogle ScholarCrossref 19.Jagota
P , Jongsuntisuk
P , Plengsri
R ,
et al. If your patients were too embarrassed to go out in public, what would you do?—public education to break the stigma on Parkinson’s disease using integrated media.
Patient Relat Outcome Meas. 2020;11:143-148. doi:
10.2147/PROM.S243990PubMedGoogle ScholarCrossref 27.World Health Organization; Food and Agriculture Organization of the United Nations. International Code of Conduct on Pesticide Management: guidelines for personal protection when handling and applying pesticide. Accessed November 23, 2021.
https://www.fao.org/3/ca7430en/CA7430EN.pdf 30.Meek
ME , Boobis
AR , Crofton
KM , Heinemeyer
G , Raaij
MV , Vickers
C . Risk assessment of combined exposure to multiple chemicals: a WHO/IPCS framework.
Regul Toxicol Pharmacol. 2011.
PubMedGoogle Scholar 35.Schwarzschild
MA , Ascherio
A , Casaceli
C ,
et al; Parkinson Study Group SURE-PD3 Investigators. Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial.
JAMA. 2021;326(10):926-939. doi:
10.1001/jama.2021.10207PubMedGoogle ScholarCrossref 40.Fothergill-Misbah
N , Maroo
H , Cham
M , Pezzoli
G , Walker
R , Cilia
R . Could Mucuna pruriens be the answer to Parkinson’s disease management in sub-Saharan Africa and other low-income countries worldwide?
Parkinsonism Relat Disord. 2020;73:3-7. doi:
10.1016/j.parkreldis.2020.03.002PubMedGoogle ScholarCrossref 47.Miyasaki
JM , Lim
SY , Chaudhuri
KR ,
et al; Task Force on Palliative Care of the International Parkinson and Movement Disorder Society. Access and attitudes toward palliative care among movement disorders clinicians.
Mov Disord. 2022;37(1):182-189.
PubMedGoogle ScholarCrossref 53.Khalil
H , Chahine
LM , Siddiqui
J ,
et al. Parkinson’s disease in the Middle East, North Africa, and South Asia: consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East.
J Parkinsons Dis. 2020;10(2):729-741. doi:
10.3233/JPD-191751PubMedGoogle ScholarCrossref